Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Monteplase is a recombinant tissue plasminogen activator (rt-PA) developed as a thrombolytic agent for the treatment of acute myocardial infarction, pulmonary embolism, and thrombosis. It is a genetically engineered mutant of tissue-type plasminogen activator with an extended half-life and reduced binding to plasminogen activator inhibitor compared to alteplase. Monteplase acts by stimulating the conversion of plasminogen to plasmin, which then degrades fibrin clots, thereby dissolving thrombi in blood vessels. It can be administered as a single intravenous bolus injection and has been shown in clinical trials to improve outcomes when used prior to percutaneous coronary intervention in acute myocardial infarction[3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on monteplase.